CoChat

FGF21 is required for protein restriction to extend lifespan and improve metabolic health in male mice

Open access

The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.

Abstract

Dietary protein restriction is increasingly recognized as a unique approach to improve metabolic health, and there is increasing interest in the mechanisms underlying this beneficial effect. Recent work indicates that the hormone FGF21 mediates the metabolic effects of protein restriction in young mice. Here we demonstrate that protein restriction increases lifespan, reduces frailty, lowers body weight and adiposity, improves physical performance, improves glucose tolerance, and alters various metabolic markers within the serum, liver, and adipose tissue of wildtype male mice. Conversely, mice lacking FGF21 fail to exhibit metabolic responses to protein restriction in early life, and in later life exhibit early onset of age-related weight loss, reduced physical performance, increased frailty, and reduced lifespan. These data demonstrate that protein restriction in aging male mice exerts marked beneficial effects on lifespan and metabolic health and that a single metabolic hormone, FGF21, is essential for the anti-aging effect of this dietary intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-29499-8

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Deletion of FGF21 reverses the beneficial effects of dietary protein restriction on lifespan. a Schematic representation of the longevity study. Wildtype and Fgf21-KO mice were placed on control or LP diet at 3 months of age and monitored until natural death. b Kaplan–Meier survival curve for wildtype mice on LP diet, indicating an extension of lifespan in WT mice on LP. n = 30 per group. c Kaplan–Meier survival curve for Fgf21-KO mice on LP, indicating a reduction in lifespan in Fgf21 KO mice on LP. n = 30 mice per group. d, e Bodyweight and bodyweight gain curves based on the initiation of diets, group*time p = 0.001. f Comparison of body weight change at specific time points, group*time p = 0.001. g Specific components were used from the Howlett Frailty Index assessed at 20 months of age, n = 9–10 mice per group; alopecia geno*diet p = 0.2115, coat condition geno*diet p = 0.0009, distended abdomen diet p = 0.0001, kyphosis geno*diet p = 0.09, body score geno*diet p = 0.2854. h, Frailty Index as an average from individual components in g, geno*diet p = 0.02. Statistical analyses were conducted using survival analysis for lifespan and one-way or two-way ANOVA for BW change and Frailty. Values are mean ± SEM, with significant posthoc comparison within the diet*genotype interaction noted as *p < 0.05 and #p < 0.10 compared with respective control. Source data are provided as a Source Data file.
Fig. 1 Deletion of FGF21 reverses the beneficial effects of dietary protein restriction on lifespan. a Schematic representation of the longevity study. Wildtype and Fgf21-KO mice were placed on control or LP diet at 3 months of age and monitored until natural death. b Kaplan–Meier survival curve for wildtype mice on LP diet, indicating an extension of lifespan in WT mice on LP. n = 30 per group. c Kaplan–Meier survival curve for Fgf21-KO mice on LP, indicating a reduction in lifespan in Fgf21 KO mice on LP. n = 30 mice per group. d, e Bodyweight and bodyweight gain curves based on the initiation of diets, group*time p = 0.001. f Comparison of body weight change at specific time points, group*time p = 0.001. g Specific components were used from the Howlett Frailty Index assessed at 20 months of age, n = 9–10 mice per group; alopecia geno*diet p = 0.2115, coat condition geno*diet p = 0.0009, distended abdomen diet p = 0.0001, kyphosis geno*diet p = 0.09, body score geno*diet p = 0.2854. h, Frailty Index as an average from individual components in g, geno*diet p = 0.02. Statistical analyses were conducted using survival analysis for lifespan and one-way or two-way ANOVA for BW change and Frailty. Values are mean ± SEM, with significant posthoc comparison within the diet*genotype interaction noted as *p < 0.05 and #p < 0.10 compared with respective control. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 FGF21 mediates low protein-induced changes in BW gain, food intake, and body composition in aged mice. a Schematic representation of the metabolic aging study. Wildtype and Fgf21-KO mice were placed on control or LP diet at 3 months of age (12 mice/group), with various metabolic endpoints assess throughout the study as indicated, and tissue collection at 22 months of age. b Body weight gain over time following initiation of experimental diets, n = 12 mice/group, group*time p = 0.001. c Final body weight gain at 22 months of age (n = 8–12 mice/group at sacrifice; geno*diet p = 0.0004). d Final body fat gain at 22 months of age as measured by NMR (n = 8–12 mice/group at sacrifice; geno*diet p = 0.03). e Final body lean gain at 22 months of age as measured by NMR (n = 8–12 mice/group at sacrifice; geno*diet p = 0.0001). f Percent body fat at 22 months of age as measured by NMR (n = 8–12 mice/group at sacrifice; geno*diet p = 0.03). g Average daily food intake throughout the study (n = 8–12 mice/group at sacrifice; geno*diet p = 0.0001). h Energy expenditure (ANCOVA adjusted for BW) as measured at 12 months of age (n = 8–12 mice/group at sacrifice; geno*diet p = 0.04). i Energy expenditure (ANCOVA adjusted for BW) as measured at 20 months of age (n = 8–12 mice/group at sacrifice; geno*diet p = 0.04). Statistical analyses were conducted using two-way ANOVA or ANCOVA. All values are mean ± SEM, with significant posthoc comparison within the diet*genotype interaction noted as *p < 0.05 compared with respective control. Source data are provided as a Source Data file.
Fig. 2 FGF21 mediates low protein-induced changes in BW gain, food intake, and body composition in aged mice. a Schematic representation of the metabolic aging study. Wildtype and Fgf21-KO mice were placed on control or LP diet at 3 months of age (12 mice/group), with various metabolic endpoints assess throughout the study as indicated, and tissue collection at 22 months of age. b Body weight gain over time following initiation of experimental diets, n = 12 mice/group, group*time p = 0.001. c Final body weight gain at 22 months of age (n = 8–12 mice/group at sacrifice; geno*diet p = 0.0004). d Final body fat gain at 22 months of age as measured by NMR (n = 8–12 mice/group at sacrifice; geno*diet p = 0.03). e Final body lean gain at 22 months of age as measured by NMR (n = 8–12 mice/group at sacrifice; geno*diet p = 0.0001). f Percent body fat at 22 months of age as measured by NMR (n = 8–12 mice/group at sacrifice; geno*diet p = 0.03). g Average daily food intake throughout the study (n = 8–12 mice/group at sacrifice; geno*diet p = 0.0001). h Energy expenditure (ANCOVA adjusted for BW) as measured at 12 months of age (n = 8–12 mice/group at sacrifice; geno*diet p = 0.04). i Energy expenditure (ANCOVA adjusted for BW) as measured at 20 months of age (n = 8–12 mice/group at sacrifice; geno*diet p = 0.04). Statistical analyses were conducted using two-way ANOVA or ANCOVA. All values are mean ± SEM, with significant posthoc comparison within the diet*genotype interaction noted as *p < 0.05 compared with respective control. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 Protein restriction protects against age-related functional decline via FGF21. a Latency to fall from an accelerating rod (Rotarod) at 21 months of age in WT and Fgf21 KO mice on control or LP diets (n = 8–12 mice/group; geno*diet p = 0.008). b Grip Strength at 21 months of age (n = 8–12 mice/group; geno*diet p = 0.04). c Grip Strength normalized to body mass (n = 8–12 mice/group; geno*diet p = 0.01). d Ambulatory activity as measured in the metabolic chambers at 20 months of age (n = 8–12 mice/group geno*diet p = 0.39). e Locomotor activity as measured in the metabolic chambers at 20 months of age (n = 8–12 mice/group geno*diet p = 0.19). Statistical analyses were conducted using two-way ANOVA. All values are mean ± SEM, with significant posthoc comparison within the diet*genotype interaction noted as *p < 0.05 compared with respective control. Source data are provided as a Source Data file.
Fig. 3 Protein restriction protects against age-related functional decline via FGF21. a Latency to fall from an accelerating rod (Rotarod) at 21 months of age in WT and Fgf21 KO mice on control or LP diets (n = 8–12 mice/group; geno*diet p = 0.008). b Grip Strength at 21 months of age (n = 8–12 mice/group; geno*diet p = 0.04). c Grip Strength normalized to body mass (n = 8–12 mice/group; geno*diet p = 0.01). d Ambulatory activity as measured in the metabolic chambers at 20 months of age (n = 8–12 mice/group geno*diet p = 0.39). e Locomotor activity as measured in the metabolic chambers at 20 months of age (n = 8–12 mice/group geno*diet p = 0.19). Statistical analyses were conducted using two-way ANOVA. All values are mean ± SEM, with significant posthoc comparison within the diet*genotype interaction noted as *p < 0.05 compared with respective control. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 FGF21 mediates low protein-induced improvements in glucose homeostasis in aged mice. a Glucose tolerance test measured at 10 months of age in WT and Fgf21 KO mice control or LP diets (n = 8–12 mice/group, group*time p = 0.001). b Area under the curve glucose as measured in the GTT at 10 months of age (n = 8–12 mice/group geno*diet p = 0.001). c Insulin tolerance test at 10 months of age (n = 8–12 mice/group, group*time p = 0.001). d Area under the curve glucose as measured in the ITT at 10 months of age (n = 8–12 mice/group; diet p = 0.001). e Glucose tolerance test measured at 18 months of age in WT and Fgf21 KO mice control or LP diets (n = 8–12 mice/group group*time p = 0.236). f Area under the curve glucose as measured in the GTT at 18 months of age (n = 8–12 mice/group) geno p = 0.004, diet p = 0.062. g Insulin tolerance test at 18 months of age (n = 8–12 mice/group group*time p = 0.001). h Area under the curve glucose as measured in the ITT at 18 months of age (n = 8–12 mice/group; diet p = 0.003). i Fasting blood glucose at 18 months of age (n = 8–12 mice/group; diet p = 0.06, geno p = 0.0031, geno*diet p = 0.128). j Serum insulin levels at sacrifice at 22 months of age (n = 8–12 mice/group; geno*diet p = 0.01). k Insulin positive area as measured via insulin IHC on fixed pancreas collected at sacrifice at 22 months of age (n = 5 mice/group; geno p = 0.001, diet p = 0.02). l Islet fractional percentage as measured on fixed pancreas collected at sacrifice at 22 months of age (n = 5 mice/group; geno p = 0.01). Statistical analyses were conducted using one or two-way ANOVA. All values are mean ± SEM, with significant posthoc comparison within the diet*genotype interaction noted as *p < 0.05, #p < 0.10 compared with respective control. Source data are provided as a Source Data file.
Fig. 4 FGF21 mediates low protein-induced improvements in glucose homeostasis in aged mice. a Glucose tolerance test measured at 10 months of age in WT and Fgf21 KO mice control or LP diets (n = 8–12 mice/group, group*time p = 0.001). b Area under the curve glucose as measured in the GTT at 10 months of age (n = 8–12 mice/group geno*diet p = 0.001). c Insulin tolerance test at 10 months of age (n = 8–12 mice/group, group*time p = 0.001). d Area under the curve glucose as measured in the ITT at 10 months of age (n = 8–12 mice/group; diet p = 0.001). e Glucose tolerance test measured at 18 months of age in WT and Fgf21 KO mice control or LP diets (n = 8–12 mice/group group*time p = 0.236). f Area under the curve glucose as measured in the GTT at 18 months of age (n = 8–12 mice/group) geno p = 0.004, diet p = 0.062. g Insulin tolerance test at 18 months of age (n = 8–12 mice/group group*time p = 0.001). h Area under the curve glucose as measured in the ITT at 18 months of age (n = 8–12 mice/group; diet p = 0.003). i Fasting blood glucose at 18 months of age (n = 8–12 mice/group; diet p = 0.06, geno p = 0.0031, geno*diet p = 0.128). j Serum insulin levels at sacrifice at 22 months of age (n = 8–12 mice/group; geno*diet p = 0.01). k Insulin positive area as measured via insulin IHC on fixed pancreas collected at sacrifice at 22 months of age (n = 5 mice/group; geno p = 0.001, diet p = 0.02). l Islet fractional percentage as measured on fixed pancreas collected at sacrifice at 22 months of age (n = 5 mice/group; geno p = 0.01). Statistical analyses were conducted using one or two-way ANOVA. All values are mean ± SEM, with significant posthoc comparison within the diet*genotype interaction noted as *p < 0.05, #p < 0.10 compared with respective control. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 FGF21-dependent and independent changes in molecular endpoints in the liver at 22 months of age. a Serum FGF21 levels collected at sacrifice at 22 months of age in WT and Fgf21 KO mice on control or LP diets as in Fig. 2 (n = 8–10 mice/group, geno*diet p = 0.01). b Liver mRNA levels for FGF21 related markers as measured via qPCR at 22 months of age (n = 8–10 mice/group, geno*diet Fgf21 p = 0.04, Fgfr1 p = 0.556, Klb = 0.3016). c Liver markers of dietary protein restriction (amino acid biosynthetic genes) as measured via qPCR at 22 months of age (n = 8–10 mice/group; geno*diet Asns p = 0.0001, Phgdh p = 0.001. d Serum IGF1 levels at sacrifice at 22 months of age (n = 8–10 mice/group; genotype p = 0.0004, diet p = 0.003, geno*diet p = 0.4567). e Liver mRNA expression for hepatic lipogenic genes as measured via qPCR at 22 months of age (n = 8–10 mice/group; Scd1 diet p = 0.001 geno*diet p = 0.553, Srebp1 diet p = 0.001, geno*diet p = 0.89, Fas diet p = 0.001 geno*diet p = 0.2395. f Liver weight as a percentage of body weight at sacrifice at 22 months of age (n = 8–10 mice/group; diet p = 0.0026, geno*diet p = 0.10). g Liver triglyceride content at sacrifice at 22 months of age (n = 8–10 mice/group, geno*diet p = 0.2271). h Serum ALT levels at sacrifice at 22 months of age (n = 8–10 mice/group; genotype p = 0.01, diet p = 0.0003, geno*diet p = 0.0057). i Serum AST levels at sacrifice at 22 months of age (n = 8–10 mice/group; genotype p = 0.6662, diet p = 0.02, geno*diet p = 0.2852). Statistical analyses were conducted using two-way ANOVA. All values are mean ± SEM, with significant main effects of diet or posthoc comparison within the diet*genotype interaction noted as *p < 0.05, #p < 0.10 compared with respective control. Source data are provided as a Source Data file.
Fig. 5 FGF21-dependent and independent changes in molecular endpoints in the liver at 22 months of age. a Serum FGF21 levels collected at sacrifice at 22 months of age in WT and Fgf21 KO mice on control or LP diets as in Fig. 2 (n = 8–10 mice/group, geno*diet p = 0.01). b Liver mRNA levels for FGF21 related markers as measured via qPCR at 22 months of age (n = 8–10 mice/group, geno*diet Fgf21 p = 0.04, Fgfr1 p = 0.556, Klb = 0.3016). c Liver markers of dietary protein restriction (amino acid biosynthetic genes) as measured via qPCR at 22 months of age (n = 8–10 mice/group; geno*diet Asns p = 0.0001, Phgdh p = 0.001. d Serum IGF1 levels at sacrifice at 22 months of age (n = 8–10 mice/group; genotype p = 0.0004, diet p = 0.003, geno*diet p = 0.4567). e Liver mRNA expression for hepatic lipogenic genes as measured via qPCR at 22 months of age (n = 8–10 mice/group; Scd1 diet p = 0.001 geno*diet p = 0.553, Srebp1 diet p = 0.001, geno*diet p = 0.89, Fas diet p = 0.001 geno*diet p = 0.2395. f Liver weight as a percentage of body weight at sacrifice at 22 months of age (n = 8–10 mice/group; diet p = 0.0026, geno*diet p = 0.10). g Liver triglyceride content at sacrifice at 22 months of age (n = 8–10 mice/group, geno*diet p = 0.2271). h Serum ALT levels at sacrifice at 22 months of age (n = 8–10 mice/group; genotype p = 0.01, diet p = 0.0003, geno*diet p = 0.0057). i Serum AST levels at sacrifice at 22 months of age (n = 8–10 mice/group; genotype p = 0.6662, diet p = 0.02, geno*diet p = 0.2852). Statistical analyses were conducted using two-way ANOVA. All values are mean ± SEM, with significant main effects of diet or posthoc comparison within the diet*genotype interaction noted as *p < 0.05, #p < 0.10 compared with respective control. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 6 FGF21-dependent and independent changes in molecular endpoints in the adipose tissue at 22 months of age. a Serum adiponectin collected at 22 months of age (n = 8–10 mice/group; geno*diet p = 0.009). b Thermogenic gene expression in inguinal white adipose tissue (iWAT) collected at sacrifice at 22 months of age (n = 8–10 mice/group; geno*diet Ucp1 p = 0.0023, Cidea p = 0.0065). c Energy metabolism gene expression in iWAT at 22 months of age (n = 8–10 mice/group; Srebp1 diet p = 0.01 geno*diet p = 0.1876, Acc1 geno*diet p = 0.002, Fas geno*diet p = 0.002, Scd1 geno*diet p = 0.1388, Pparg geno*diet p = 0.6344, Ppara geno*diet p = 0.01, Pgc1a geno*diet p = 0.02). d Expression of thermogenic markers within BAT (n = 3–10 mice/group; Ucp1 geno*diet p = 0.6124, Cidea geno*diet p = 0.5739, Dio2 diet p = 0.05 geno*diet p = 0.99, Pgc1a diet p = 0.007 geno*diet p = 0.37, Prdm16 geno p = 0.0079 geno*diet p = 0.37). e Expression of inflammatory markers within visceral adipose tissue (n = 8–10 mice/group; Adgre geno*diet p = 0.009, Cd68 p = 0.006, Arg1 geno*diet p = 0.01, Itgam diet p = 0.002 geno p = 0.03 geno*diet p = 0.14, IL1b geno*diet p = 0.9, IL6 geno*diet p = 0.67). Statistical analyses were conducted using two-way ANOVA. All values are mean ± SEM, with significant main effects of diet or posthoc comparison within the diet*genotype interaction noted as *p < 0.05, #p < 0.10 compared with respective control. Source data are provided as a Source Data file.
Fig. 6 FGF21-dependent and independent changes in molecular endpoints in the adipose tissue at 22 months of age. a Serum adiponectin collected at 22 months of age (n = 8–10 mice/group; geno*diet p = 0.009). b Thermogenic gene expression in inguinal white adipose tissue (iWAT) collected at sacrifice at 22 months of age (n = 8–10 mice/group; geno*diet Ucp1 p = 0.0023, Cidea p = 0.0065). c Energy metabolism gene expression in iWAT at 22 months of age (n = 8–10 mice/group; Srebp1 diet p = 0.01 geno*diet p = 0.1876, Acc1 geno*diet p = 0.002, Fas geno*diet p = 0.002, Scd1 geno*diet p = 0.1388, Pparg geno*diet p = 0.6344, Ppara geno*diet p = 0.01, Pgc1a geno*diet p = 0.02). d Expression of thermogenic markers within BAT (n = 3–10 mice/group; Ucp1 geno*diet p = 0.6124, Cidea geno*diet p = 0.5739, Dio2 diet p = 0.05 geno*diet p = 0.99, Pgc1a diet p = 0.007 geno*diet p = 0.37, Prdm16 geno p = 0.0079 geno*diet p = 0.37). e Expression of inflammatory markers within visceral adipose tissue (n = 8–10 mice/group; Adgre geno*diet p = 0.009, Cd68 p = 0.006, Arg1 geno*diet p = 0.01, Itgam diet p = 0.002 geno p = 0.03 geno*diet p = 0.14, IL1b geno*diet p = 0.9, IL6 geno*diet p = 0.67). Statistical analyses were conducted using two-way ANOVA. All values are mean ± SEM, with significant main effects of diet or posthoc comparison within the diet*genotype interaction noted as *p < 0.05, #p < 0.10 compared with respective control. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 7 Protein restriction promotes beneficial metabolic effects and protects against diet-induced obesity when initiated at middle age. a Schematic representation of middle-aged study. Wildtype and Fgf21-KO mice were placed on CON, LP, HFCON, or HFLP diet at 12 months of age, with various metabolic endpoints assessed throughout the study as indicated and tissue collection at 16 months of age. b Body weight gain from initiation of diets (n = 12 mice/group). c Body weight gain from diet initiation to sacrifice at 16 months of age (n = 8–12 mice/group; fat p < 0.0001, protein p = 0.0046, fat*protein p = 0.8814). d Body fat gain from diet initiation to sacrifice at 16 months of age, as measured by NMR (n = 6–12 mice/group; fat p < 0.0001, protein p < 0.0001, fat*protein p = 0.816). e Body lean gain from diet initiation to sacrifice at 16 months of age, as measured by NMR (n = 6–12 mice/group; fat p = 0.001, protein p = 0.001, fat*protein p = 0.0144. f Percent body fat at sacrifice at 16 months of age (n = 6–12 mice/group; fat p < 0.0001, protein p < 0.0001, fat*protein p = 0.218). g Average daily food intake throughout the experiment (n = 4 cages/group fat p = 0.6676, protein p = 0.0001, fat*protein p = 0.285). h Glucose tolerance test conducted at 14 months of age (2 months on diet (n = 6–8 mice/group; group*time p = 0.001). i Area under the curve glucose for the GTT at 14 months of age (n = 6–8 mice/group fat*protein p = 0.01). j Fasting blood glucose at 14 months of age (n = 6–8 mice/group; fat p = 0.0001, protein p = 0.0001, fat*protein p = 0.94). k Serum insulin levels at sacrifice at 14 months of age (n = 6–8 mice/group; fat p = 0.0033, protein p = 0.0001, fat*protein p = 0.4746). Statistical analyses were conducted using two-way ANOVA with dietary fat content and dietary protein content as main effects. All values are mean ± SEM, with significant main effects of protein or posthoc comparisons within the fat*protein interaction noted as *p < 0.05 vs respective control, and main effects of fat noted as &p < 0.05 HFCON vs CON. Source data are provided as a Source Data file.
Fig. 7 Protein restriction promotes beneficial metabolic effects and protects against diet-induced obesity when initiated at middle age. a Schematic representation of middle-aged study. Wildtype and Fgf21-KO mice were placed on CON, LP, HFCON, or HFLP diet at 12 months of age, with various metabolic endpoints assessed throughout the study as indicated and tissue collection at 16 months of age. b Body weight gain from initiation of diets (n = 12 mice/group). c Body weight gain from diet initiation to sacrifice at 16 months of age (n = 8–12 mice/group; fat p < 0.0001, protein p = 0.0046, fat*protein p = 0.8814). d Body fat gain from diet initiation to sacrifice at 16 months of age, as measured by NMR (n = 6–12 mice/group; fat p < 0.0001, protein p < 0.0001, fat*protein p = 0.816). e Body lean gain from diet initiation to sacrifice at 16 months of age, as measured by NMR (n = 6–12 mice/group; fat p = 0.001, protein p = 0.001, fat*protein p = 0.0144. f Percent body fat at sacrifice at 16 months of age (n = 6–12 mice/group; fat p < 0.0001, protein p < 0.0001, fat*protein p = 0.218). g Average daily food intake throughout the experiment (n = 4 cages/group fat p = 0.6676, protein p = 0.0001, fat*protein p = 0.285). h Glucose tolerance test conducted at 14 months of age (2 months on diet (n = 6–8 mice/group; group*time p = 0.001). i Area under the curve glucose for the GTT at 14 months of age (n = 6–8 mice/group fat*protein p = 0.01). j Fasting blood glucose at 14 months of age (n = 6–8 mice/group; fat p = 0.0001, protein p = 0.0001, fat*protein p = 0.94). k Serum insulin levels at sacrifice at 14 months of age (n = 6–8 mice/group; fat p = 0.0033, protein p = 0.0001, fat*protein p = 0.4746). Statistical analyses were conducted using two-way ANOVA with dietary fat content and dietary protein content as main effects. All values are mean ± SEM, with significant main effects of protein or posthoc comparisons within the fat*protein interaction noted as *p < 0.05 vs respective control, and main effects of fat noted as &p < 0.05 HFCON vs CON. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 8 Serum, liver, and adipose tissue endpoints following the initiation of dietary protein restriction in middle age. a Serum FGF21 concentrations in wildtype and Fgf21-KO mice consuming control or LP diet from 12 to 16 months of age as Fig. 7a (n = 6–10 mice/group; protein p = 0.0002). b Serum Adiponectin concentrations at 16 months of age (n = 6–10 mice/group; fat p = 0.0007, protein p = 0.004). c Liver triglyceride content at 16 months of age (n = 6–10 mice/group; fat p = 0.0023, protein p = 0.06, fat*protein p = 0.11). d Liver amino acid biosynthetic gene expression (markers of dietary protein restriction) as measured via qPCR at 16 months of age (n = 6–10 mice/group; Asns protein p = 0.003, Phgdh protein p = 0.02). e Liver mRNA expression of FGF21 signaling genes as measured via qPCR at 16 months of age (n = 6–10 mice/group; Fgf21 protein p = 0.01, Klb fat p = 0.001, protein p = 0.01, fat*protein p = 0.08, Fgfr1 fat p = 0.04, protein p = 0.01) f Liver mRNA expression of lipogenic genes as measured via qPCR at 16 months of age (n = 6–10 mice/group, Scd1 fat p = 0.008, protein p = 0.0002, Srebp1 fat p = 0.04, protein p = 0.009, Fas fat p = 0.01, protein p = 0.001). g iWAT expression of Ucp1 at 16 months of age (n = 6–10 mice/group; fat*protein p = 0.02). h iWAT expression of Cidea at 16 months of age (n = 6–10 mice/group; fat*protein p = 0.03). i iWAT expression of metabolic genes at 16 months of age (n = 6–10 mice/group; Srebp1 p = NS, Acc1 fat*protein p = 0.08, Fas fat p = 0.04, Scd1 fat p = 0.08, protein p = 0.008, Pparg p = NS, Ppara fat*protein p = 0.06, Pgc1a fat p = 0.03). Statistical analyses were conducted using two-way ANOVA. All values are mean ± SEM, with significant main effects of protein or posthoc comparison within the fat*protein interaction noted as *p < 0.05 vs respective control and main effects of fat noted as &p < 0.05 HFCON vs CON. Source data are provided as a Source Data file.
Fig. 8 Serum, liver, and adipose tissue endpoints following the initiation of dietary protein restriction in middle age. a Serum FGF21 concentrations in wildtype and Fgf21-KO mice consuming control or LP diet from 12 to 16 months of age as Fig. 7a (n = 6–10 mice/group; protein p = 0.0002). b Serum Adiponectin concentrations at 16 months of age (n = 6–10 mice/group; fat p = 0.0007, protein p = 0.004). c Liver triglyceride content at 16 months of age (n = 6–10 mice/group; fat p = 0.0023, protein p = 0.06, fat*protein p = 0.11). d Liver amino acid biosynthetic gene expression (markers of dietary protein restriction) as measured via qPCR at 16 months of age (n = 6–10 mice/group; Asns protein p = 0.003, Phgdh protein p = 0.02). e Liver mRNA expression of FGF21 signaling genes as measured via qPCR at 16 months of age (n = 6–10 mice/group; Fgf21 protein p = 0.01, Klb fat p = 0.001, protein p = 0.01, fat*protein p = 0.08, Fgfr1 fat p = 0.04, protein p = 0.01) f Liver mRNA expression of lipogenic genes as measured via qPCR at 16 months of age (n = 6–10 mice/group, Scd1 fat p = 0.008, protein p = 0.0002, Srebp1 fat p = 0.04, protein p = 0.009, Fas fat p = 0.01, protein p = 0.001). g iWAT expression of Ucp1 at 16 months of age (n = 6–10 mice/group; fat*protein p = 0.02). h iWAT expression of Cidea at 16 months of age (n = 6–10 mice/group; fat*protein p = 0.03). i iWAT expression of metabolic genes at 16 months of age (n = 6–10 mice/group; Srebp1 p = NS, Acc1 fat*protein p = 0.08, Fas fat p = 0.04, Scd1 fat p = 0.08, protein p = 0.008, Pparg p = NS, Ppara fat*protein p = 0.06, Pgc1a fat p = 0.03). Statistical analyses were conducted using two-way ANOVA. All values are mean ± SEM, with significant main effects of protein or posthoc comparison within the fat*protein interaction noted as *p < 0.05 vs respective control and main effects of fat noted as &p < 0.05 HFCON vs CON. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Cited by

See all 117

Metadata

Authors
Hill, C. M., Albarado, D. C., Coco, L. G., Spann, R. A., Khan, M. S., Qualls-Creekmore, E., Burk, D. H., Burke, S. J., Collier, J. J., Yu, S., McDougal, D. H., Berthoud, H.-R., Münzberg, H., Bartke, A., & Morrison, C. D.
Affiliations
  • Pennington Biomedical Research Center (US)
  • SIU Medicine (US)
Corresponding author
  • Hill, Cristal M.
  • Morrison, Christopher D.
Venue
Nature Communications
Published
2022-04-07
Volume
13
Issue
1
Pages
1897-1897
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4223621452
Cited by
117
References
75
Citations by year
2026: 27 · 2025: 29 · 2024: 27 · 2023: 24 · 2022: 10
FWCI
7.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Civil War Book Review (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (F32DK115137, R01DK123183, R01DK047348, R01DK092587, R01DK105032, R01DK121370, R01DK123083)
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R21AI138136)
  • U.S. Department of Health & Human Services | NIH | National Institute on Aging (R21AG062985)
  • American Diabetes Association (1-19-IBS-126)
  • U.S. Department of Health & Human Services | NIH | NIH Office of the Director (S10OD023703)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Physiology (medical) › Dietary Effects on Health
Keywords
FGF21, protein restriction, lifespan extension, aging, metabolic health, frailty, glucose tolerance, adiposity, physical performance, anti-aging diet, FGF21 knockout mice
MeSH terms
Frailty, Animals, Fibroblast Growth Factors, Hormones, Liver, Longevity, Male, Diet, Protein-Restricted, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FGF21 is required for protein restriction to extend lifespan and improve metabolic health in male mice. https://app.cochat.ai/papers/10.1038/s41467-022-29499-8
The paper
Hill, C. M., Albarado, D. C., Coco, L. G., Spann, R. A., Khan, M. S., Qualls-Creekmore, E., Burk, D. H., Burke, S. J., Collier, J. J., Yu, S., McDougal, D. H., Berthoud, H.-R., Münzberg, H., Bartke, A., & Morrison, C. D. (2022). FGF21 is required for protein restriction to extend lifespan and improve metabolic health in male mice. Nature Communications. https://doi.org/10.1038/s41467-022-29499-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.